Trial Profile
A Randomised, Double-blind, Placebo-controlled (Within Dose Groups) Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses (0.5 μg to 70 μg Administered With the Respimat of BI 11054 CL in Healthy Male Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs BI 11054 (Primary)
- Indications Unspecified
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Boehringer Ingelheim
- 21 Nov 2014 New trial record